Eli Lilly, Purdue create $250 million partnership for pharma research as federal cuts hit labs
Eli Lilly and Purdue University are changing how groundbreaking research can be funded as universities and labs across the country grapple with sudden federal funding cuts to vital research.
Lilly CEO Dave Ricks and Purdue University President Mung Chiang on May 9 announced a $250 million collaboration to build up pharmaceutical technology in what the two Indiana leaders believe is the largest industry-academic partnership in the country.
"It will be focused on accelerating innovation at every stage of the work we do," Ricks said. "And then also on talent, training the workforce of the future to work at Lilly and other advanced pharmaceutical companies."
Over the next eight years, Lilly and Purdue will use the investment to speed up several areas of innovation in the pharmaceutical industry, including using AI-powered tools to augment traditional drug discovery methods; incorporating robotics to scale manufacturing capacity; and facilitating the drug pipeline at the future Lilly Medicine Foundry in Lebanon.
An existing partnership was set to expire in 2027, but this program, named the Lilly-Purdue 360 initiative, will expand the collaboration and keep it running until at least 2032.
The announcement comes as universities are grappling with how to respond to a sudden loss of money from the federal government. Some universities are laying off employees or dipping into endowment funds to keep labs afloat.
Chiang said industry partnerships can be used to cover gaps in federal funding, but he cautioned against universities relying exclusively on industry support. He believes Purdue "can win" with a steady combination of industry and federal funding well into the future.
"With today's announcement, Lilly and Purdue is taking a leadership position across the entire country with the largest such agreement in scale and perhaps in scope, too, to demonstrate what we can do together," Chiang said. "Now this may not be the only part of the future of research, but it certainly is an increasingly important part and we are proud of a nationally leading agreement today."
As part of the agreement, Purdue will make space available for Lilly researchers to work on site at the West Lafayette campus while Purdue researchers will collaborate at Lilly sites in Indianapolis and at the LEAP District along I-65 in Boone County.
Dave Ricks on tariffs: Eli Lilly CEO says tariffs are not the answer, urges Trump to move fast on trade deals
The Lilly-Purdue partnership will strengthen the university's Lilly Scholars program, which provides full-ride scholarships and paid internships to Purdue undergraduates in STEM. The scholars program is one way Lilly hopes to keep talent in Indiana after they graduate college.
Meanwhile, Lilly is continuing to increase how much medicine is manufactured in the United States, a move that could require additional employees. The pharmaceutical giant broke ground on its Medicine Foundry at the LEAP District in Lebanon earlier in the week, a first of its kind facility where clinical trials will be conducted and medicine manufactured.
Earlier this year, Lilly announced a $27 billion investment to build four new American manufacturing facilities. Upon completion, Lilly will be able to supply medicine in the U.S. completely from U.S. facilities, Ricks previously said.
Jason Thiagarajan, a Purdue sophomore from Bloomington in the Lilly Scholars program, said he hopes the investment will increase mentorship in the program and keep more young professionals like him in the state well into their careers.
"I've never been more proud to be born and raised in Indiana," Thiagarajan said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years
Druckenmiller has a stunning investment track record, regularly delivering double-digit percentage annual returns with no money-losing years. In recent times, the billionaire has benefited from investments in some of today's top growth stocks. 10 stocks we like better than Eli Lilly › You don't have to be a billionaire to invest like one -- and reap the rewards. Any of us can look at the moves made by the world's most successful investors and follow those that also fit into our investment strategy. Billionaire fund managers have proven their strengths as investors over time, making them excellent guides for novices on the wealth-building path. With that in mind, let's consider the recent moves made by Stanley Druckenmiller, founder of the Duquesne Family Office. Over the past few quarters, he closed his position in last year's two top-performing S&P 500 and Dow Jones Industrial Average artificial intelligence (AI) stocks, and just recently, he increased his position in a growth stock that has soared by 150% over the past three years. Could taking those cues be a smart move for you? So, first, a bit about why Druckenmiller is a billionaire worth watching and potentially following. He founded Duquesne Capital Management in the early 1980s and ran the fund for 30 years. Over that time period, he delivered a truly remarkable annualized average return of 30% -- and importantly, never had a money-losing year. Since then, he has shifted his focus to his family office, where he invests in stocks across industries and oversees $3 billion in securities. Now, let's consider his recent moves, starting with a major one. In the third quarter, Druckenmiller closed out his position in AI chip market leader Nvidia (NASDAQ: NVDA), a company that climbed a bit further from there, becoming the Dow Jones Industrial Average component that delivered the biggest annual gain of 2024. The investor originally bought Nvidia shares in the fourth quarter of 2022, and from the end of that quarter through the end of last year's third quarter, they climbed by more than 700%. So this clearly was a winning investment for Druckenmiller, though in a Bloomberg interview, he expressed regret about the timing of the sale, and said he would consider buying Nvidia stock again at the right price. Druckenmiller's second big sale came in the first quarter of this year: He closed out his position in Palantir Technologies (NASDAQ: PLTR), a stock he bought a year earlier. Last year, the AI software company generated the biggest gain in the S&P 500, climbing by 340%. Meanwhile, Druckenmiller increased his position in another growth stock: pharma giant Eli Lilly (NYSE: LLY), which in recent quarters has delivered double-digit percentage revenue gains. That growth came largely thanks to its position in a high-growth market with solid long-term potential: weight loss drugs. Druckenmiller increased his Lilly holding by 52% in the first quarter and now owns 94,830 shares worth about $73 million as of the close of trading Friday. Lilly represents nearly 2.6% of the billionaire's portfolio, up from about 1.3% in the previous quarter. He initially bought the stock in 2024's fourth quarter, so he clearly is building a position in it, and sees opportunity for growth ahead. Lilly sells a wide variety of medicines, but investors have focused on its GLP-1 agonist tirzepatide in recent quarters -- and for good reason. Tirzepatide is sold under the name Mounjaro for type 2 diabetes and Zepbound for weight loss, and both drugs are generating blockbuster revenues. Doctors have prescribed either one for weight loss, and demand has been so high that last year, both were on the Food and Drug Administration's shortage list. These drugs should continue to generate sales growth due to ongoing high demand; analysts at Goldman Sachs forecast that the weight loss drug market will be about $95 billion annually by 2030. One more element may supercharge Lilly's growth in this market. Mounjaro, Zepbound, and the competing GLP-1 drugs on the market today all must be administered via injection, but Lilly has been developing a new weight loss candidate in pill form. Phase 3 trials have produced strong data for the pill, dubbed orforglipron, and Lilly says it will apply for regulatory review in the weight loss indication by the end of this year. The convenience of a weight loss pill that is as effective as the injectables could help orforglipron (and Lilly) take a leading share of the market in the years to come. So the drugmaker's growth may be far from over. Should you follow Druckenmiller's lead, exit Nvidia and Palantir (if you own them), and get in on Lilly shares? All three of these companies are leaders in exciting growth markets and could gain over the long term, so your decisions should depend on your investment strategy. If you're a cautious investor and like passive income, Eli Lilly is a great choice to own because, while it does offer share price growth potential, it also offers the safety and steady dividends of an established pharma player. If you're an aggressive investor, though, you may want to favor the AI story and continue along with Nvidia and/or Palantir over the long term. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool has a disclosure policy. Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years was originally published by The Motley Fool
Yahoo
12 hours ago
- Yahoo
See Purdue's 50-year plan to transform downtown Indianapolis campus with high-rises
Over the next 50 years, Purdue University plans to transform its downtown Indianapolis campus into an urban hub with high-rise buildings hosting up to 15,000 students, according to a new master plan. Today, Purdue's 28-acre sliver of land wedged between Indiana Avenue and Michigan Street on downtown's west side — roughly the same acreage as the parcel on which Lucas Oil Stadium and its south parking lot sit — is home to three parking garages and five expansive parking lots. A conceptual master plan approved by Purdue's Board of Trustees June 6 envisions 16 new buildings on that site, featuring 4.5 million square feet and about 3,500 student beds. With leasing agreements at nearby apartments, Purdue expects to offer students more than 5,300 beds downtown. The plan foresees an increase in Purdue's student enrollment in Indianapolis from about 2,800 in fall 2024 to 15,000 by fall 2075. Despite the dense development, the plan sets aside about 60% of the downtown acreage for open spaces where students can gather and walk, according to Maryland-based architecture firm Ayers Saint Gross, which designed the 50-year master plan. Construction on the campus' main building, the 15-story Academic Success Building near the intersection of West and Michigan streets, began this April. The $187 million facility with classrooms, lab space, dining halls and student housing will be complete around May 2027. The long-term plan comes as Purdue and Indiana University in Indianapolis jostle for position on the west side of downtown following the 2024 split of the two schools' joint urban campus, IUPUI. As Purdue updates its plans, IU has allotted hundreds of millions of dollars to build multiple major facilities, including an 11-story School of Medicine building and a 4,500-seat athletics center, on its downtown campus in the next few years. IUPUI split: Indiana Ave. fell as IUPUI rose. After Purdue and IU split, can they help renew the Avenue? After the IUPUI division, IU retains most of the 536-acre downtown campus and enrolled more than 25,000 students in fall 2024. IU also owns the 28-acre wedge of land where Purdue will expand between Indiana Avenue to the north, Michigan Street to the south and Blake Street to the west. Purdue has signed a 100-year lease to use the property. Purdue is expanding into Indiana's capital city in part to ease the strain on housing and other facilities at the West Lafayette campus, which now enrolls an all-time high of more than 55,000 students. University leaders have also announced partnerships with Indianapolis-based science and engineering firms like animal health company Elanco and race car manufacturer Dallara. 'Rather than a single hub, Purdue is weaving into the fabric of the city's innovation and industry corridors," David Umulis, Purdue's senior vice provost for Indianapolis, said in a statement, "expanding from downtown all the way to the northwest side of Indianapolis." Email IndyStar Reporter Jordan Smith at JTsmith@ Follow him on X: @jordantsmith09 This article originally appeared on Indianapolis Star: What's in Purdue's 50-year plan for downtown Indianapolis campus
Indianapolis Star
14 hours ago
- Indianapolis Star
See Purdue's 50-year plan to transform downtown Indianapolis campus with high-rises
Over the next 50 years, Purdue University plans to transform its downtown Indianapolis campus into an urban hub with high-rise buildings serving up to 15,000 students, according to a new master plan. Today, Purdue's 28-acre sliver of land wedged between Indiana Avenue and Michigan Street on downtown's west side — roughly the same acreage as the parcel on which Lucas Oil Stadium and its south parking lot sit — is home to three parking garages and five expansive parking lots. A conceptual master plan approved by Purdue's Board of Trustees June 6 envisions 16 new buildings on that site, featuring 4.5 million square feet and about 3,500 student beds. With leasing agreements at nearby apartments, Purdue expects to offer students more than 5,300 beds downtown. The plan foresees an increase in Purdue's student enrollment in Indianapolis from about 2,800 in fall 2024 to 15,000 by fall 2075. Despite the dense development, the plan sets aside about 60% of the downtown acreage for open spaces where students can gather and walk, according to Maryland-based architecture firm Ayers Saint Gross, which designed the 50-year master plan. Construction on the campus' main building, the 15-story Academic Success Building near the intersection of West and Michigan streets, began this April. The $187 million facility with classrooms, lab space, dining halls and student housing will be complete around May 2027. The long-term plan comes as Purdue and Indiana University in Indianapolis jostle for position on the west side of downtown following the 2024 split of the two schools' joint urban campus, IUPUI. As Purdue updates its plans, IU has allotted hundreds of millions of dollars to build multiple major facilities, including an 11-story School of Medicine building and a 4,500-seat athletics center, on its downtown campus in the next few years. IUPUI split: Indiana Ave. fell as IUPUI rose. After Purdue and IU split, can they help renew the Avenue? After the IUPUI division, IU retains most of the 536-acre downtown campus and enrolled more than 25,000 students in fall 2024. IU also owns the 28-acre wedge of land where Purdue will expand between Indiana Avenue to the north, Michigan Street to the south and Blake Street to the west. Purdue has signed a 100-year lease to use the property. Purdue is expanding into Indiana's capital city in part to ease the strain on housing and other facilities at the West Lafayette campus, which now enrolls an all-time high of more than 55,000 students. University leaders have also announced partnerships with Indianapolis-based science and engineering firms like animal health company Elanco and race car manufacturer Dallara. 'Rather than a single hub, Purdue is weaving into the fabric of the city's innovation and industry corridors," David Umulis, Purdue's senior vice provost for Indianapolis, said in a statement, "expanding from downtown all the way to the northwest side of Indianapolis."
